BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11689082)

  • 1. Structure-activity studies of the Phe(4) residue of nociceptin(1-13)-NH(2): identification of highly potent agonists of the nociceptin/orphanin FQ receptor.
    Guerrini R; Caló G; Bigoni R; Rizzi D; Rizzi A; Zucchini M; Varani K; Hashiba E; Lambert DG; Toth G; Borea PA; Salvadori S; Regoli D
    J Med Chem; 2001 Nov; 44(23):3956-64. PubMed ID: 11689082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)amide analogues. 1. In vitro studies.
    Bigoni R; Rizzi D; Rizzi A; Camarda V; Guerrini R; Lambert DG; Hashiba E; Berger H; Salvadori S; Regoli D; Calo' G
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Jun; 365(6):442-9. PubMed ID: 12070757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further studies on nociceptin-related peptides: discovery of a new chemical template with antagonist activity on the nociceptin receptor.
    Guerrini R; Caló G; Bigoni R; Rizzi A; Varani K; Toth G; Gessi S; Hashiba E; Hashimoto Y; Lambert DG; Borea PA; Tomatis R; Salvadori S; Regoli D
    J Med Chem; 2000 Jul; 43(15):2805-13. PubMed ID: 10956188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands.
    Guerrini R; Caló G; Lambert DG; Carrá G; Arduin M; Barnes TA; McDonald J; Rizzi D; Trapella C; Marzola E; Rowbotham DJ; Regoli D; Salvadori S
    J Med Chem; 2005 Mar; 48(5):1421-7. PubMed ID: 15743186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of [(pF)Phe(4)]nociceptin/orphanin FQ-(1-13)NH(2) on GTPgamma(35)S binding and cAMP formation in Chinese hamster ovary cells expressing the human nociceptin/orphanin FQ receptor.
    McDonald J; Barnes TA; Calo G; Guerrini R; Rowbotham DJ; Lambert DG
    Eur J Pharmacol; 2002 May; 443(1-3):7-12. PubMed ID: 12044785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1-14)NH2.
    Kitayama M; Barnes TA; Carra G; McDonald J; Calo G; Guerrini R; Rowbotham DJ; Smith G; Lambert DG
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Dec; 368(6):528-37. PubMed ID: 14598020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of [Phe1psi(CH2-NH)Gly2]nociceptin(1-13)NH2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin receptors.
    Okawa H; Nicol B; Bigoni R; Hirst RA; Calo G; Guerrini R; Rowbotham DJ; Smart D; McKnight AT; Lambert DG
    Br J Pharmacol; 1999 May; 127(1):123-30. PubMed ID: 10369464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)NH2 analogues. 2. In vivo studies.
    Rizzi A; Salis MB; Ciccocioppo R; Marzola G; Bigoni R; Guerrini R; Massi M; Madeddu P; Salvadori S; Regoli D; Calo' G
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Jun; 365(6):450-6. PubMed ID: 12070758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the activity of a novel nociceptin/orphanin FQ analogue at recombinant human nociceptin/orphanin FQ receptors expressed in Chinese hamster ovary cells.
    Wright KE; McDonald J; Barnes TA; Rowbotham DJ; Guerrini R; Calo' G; Lambert DG
    Neurosci Lett; 2003 Aug; 346(3):145-8. PubMed ID: 12853105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro agonist effects of nociceptin and [Phe(1)psi(CH(2)-NH)Gly(2)]nociceptin(1-13)NH(2) in the mouse and rat colon and the mouse vas deferens.
    Menzies JR; Glen T; Davies MR; Paterson SJ; Corbett AD
    Eur J Pharmacol; 1999 Dec; 385(2-3):217-23. PubMed ID: 10607879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity studies on different modifications of nociceptin/orphanin FQ: identification of highly potent agonists and antagonists of its receptor.
    Chang M; Peng YL; Dong SL; Han RW; Li W; Yang DJ; Chen Q; Wang R
    Regul Pept; 2005 Sep; 130(3):116-22. PubMed ID: 15935490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist.
    Calo' G; Guerrini R; Bigoni R; Rizzi A; Bianchi C; Regoli D; Salvadori S
    J Med Chem; 1998 Aug; 41(18):3360-6. PubMed ID: 9719588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide.
    Guerrini R; Calo G; Rizzi A; Bianchi C; Lazarus LH; Salvadori S; Temussi PA; Regoli D
    J Med Chem; 1997 Jun; 40(12):1789-93. PubMed ID: 9191955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro characterization of Ac-RYYRWK-NH(2), Ac-RYYRIK-NH(2) and [Phe1Psi(CH(2)-NH)Gly2] nociceptin(1-13)NH(2) at rat native and recombinant ORL(1) receptors.
    Mason SL; Ho M; Nicholson J; McKnight AT
    Neuropeptides; 2001; 35(5-6):244-56. PubMed ID: 12030809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonist-regulated internalization and desensitization of the human nociceptin receptor expressed in CHO cells.
    Spampinato S; Baiula M; Calienni M
    Curr Drug Targets; 2007 Jan; 8(1):137-46. PubMed ID: 17266537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nociceptin peptides.
    Ambo A; Hamazaki N; Yamada Y; Nakata E; Sasaki Y
    J Med Chem; 2001 Nov; 44(23):4015-8. PubMed ID: 11689089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationship of [Nphe1]-NC-(1-13)-NH2, a pure and selective nociceptin/orphanin FQ receptor antagonist.
    Guerrini R; Calo' G; Bigoni R; Rizzi D; Regoli D; Salvadori S
    J Pept Res; 2001 Mar; 57(3):215-22. PubMed ID: 11298922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonistic effects of [Nphe1]nociceptin(1-13)NH2 on nociceptin receptor mediated inhibition of cAMP formation in Chinese hamster ovary cells stably expressing the recombinant human nociceptin receptor.
    Hashimoto Y; Caló G; Guerrini R; Smith G; Lambert DG
    Neurosci Lett; 2000 Jan; 278(1-2):109-12. PubMed ID: 10643813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A structure-activity study of nociceptin-(1-13)-peptide amide. Synthesis of analogues substituted in positions 0, 1, 3, 4 and 10.
    Bobrova I; Vlaskovska M; Kasakov L; Surovoy A; Egorova N; Johansson L; Karsnas P; Terenius L
    Eur J Med Chem; 2003; 38(7-8):687-94. PubMed ID: 12932899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Calpha,alpha-dialkylated amino acids.
    Arduin M; Spagnolo B; Calò G; Guerrini R; Carrà G; Fischetti C; Trapella C; Marzola E; McDonald J; Lambert DG; Regoli D; Salvadori S
    Bioorg Med Chem; 2007 Jul; 15(13):4434-43. PubMed ID: 17490886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.